| 08/14/2026 3:50 PM | Jade Biosciences (1798749) Subject Venrock Healthcare Capital Partners III, L.P. (1738048) Filed by | Form SCHEDULE 13G/A | |
| 08/14/2026 10:57 AM | Bellevue Group AG (1674546) Filed by Jade Biosciences (1798749) Subject | Form SCHEDULE 13G/A | |
| 08/10/2026 6:13 AM | Jade Biosciences (1798749) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 08/10/2026 6:21 AM | Jade Biosciences (1798749) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 07/17/2026 3:05 PM | Jade Biosciences (1798749) Subject Paradigm Biocapital Advisors LP (1855655) Filed by | Form SCHEDULE 13G | |
| 07/08/2026 4:43 PM | Jade Biosciences (1798749) Subject Janus Henderson Group Ltd. (1274173) Filed by | Form SCHEDULE 13G/A | |
| 07/01/2026 3:41 PM | Jade Biosciences (1798749) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/26/2026 8:11 PM | Eisner Mark (1834161) Reporting Jade Biosciences (1798749) Issuer | Form 3 Initial statement of beneficial ownership of securities | |
| 06/26/2026 8:20 PM | Eisner Mark (1834161) Reporting Jade Biosciences (1798749) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/26/2026 6:15 AM | Jade Biosciences (1798749) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/11/2026 3:41 PM | Jade Biosciences (1798749) Issuer Klein Lawrence Otto (1762583) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
Get the Latest News and Ratings for JBIO and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Jade Biosciences and its competitors with MarketBeat's FREE daily newsletter.
|
| 06/11/2026 3:42 PM | DOBMEIER ERIC (1202785) Reporting Jade Biosciences (1798749) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/11/2026 3:47 PM | CAIN CHRISTOPHER W. (1817733) Reporting Jade Biosciences (1798749) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/11/2026 3:37 PM | Fairmount Funds Management LLC (1802528) Reporting Fairmount Healthcare Co-Invest IV L.P. (2042283) Reporting Fairmount Healthcare Fund II L.P. (1769651) Reporting Harwin Peter Evan (1663607) Reporting Jade Biosciences (1798749) Issuer Kiselak Tomas (1830177) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/11/2026 3:37 PM | Jade Biosciences (1798749) Issuer Lavelle Erin (1737613) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 06/09/2026 4:30 PM | Fairmount Funds Management LLC (1802528) Filed by Jade Biosciences (1798749) Subject | Form SCHEDULE 13D/A | |
| 06/04/2026 4:07 PM | Jade Biosciences (1798749) Filer | Form 424B5 | |
| 06/04/2026 4:09 PM | Jade Biosciences (1798749) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 06/01/2026 6:55 AM | Jade Biosciences (1798749) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 05/17/2026 11:15 PM | Jade Biosciences (1798749) Filer | Form EFFECT | |
| 05/17/2026 11:15 PM | Jade Biosciences (1798749) Filer | Form EFFECT | |
| 05/15/2026 3:44 PM | Jade Biosciences (1798749) Filer | Form 424B3 | |
| 05/15/2026 11:38 AM | Jade Biosciences (1798749) Subject JANUS HENDERSON GROUP PLC (1274173) Filed by | Form SCHEDULE 13G/A | |
| 05/07/2026 4:26 PM | Jade Biosciences (1798749) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 05/07/2026 4:15 PM | Jade Biosciences (1798749) Filer | Form S-3 Registration statement under Securities Act of 1933 | |
| 05/07/2026 4:20 PM | Jade Biosciences (1798749) Filer | Form S-3 Registration statement under Securities Act of 1933 | |
| 05/07/2026 3:33 PM | Jade Biosciences (1798749) Filer | Form 424B3 | |
| 05/07/2026 3:35 PM | Jade Biosciences (1798749) Filer | Form 424B3 | |
| 04/28/2026 3:15 PM | Jade Biosciences (1798749) Filer | Form ARS | |
| 04/27/2026 3:12 PM | BlackRock, Inc. (2012383) Filed by Jade Biosciences (1798749) Subject | Form SCHEDULE 13G/A | |
| 04/22/2026 6:18 AM | Jade Biosciences (1798749) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 04/17/2026 3:18 PM | Jade Biosciences (1798749) Filer | Form PRE 14A | |
| 04/02/2026 3:10 PM | Jade Biosciences (1798749) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/06/2026 3:49 PM | Jade Biosciences (1798749) Filer | Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
| 03/06/2026 3:34 PM | Jade Biosciences (1798749) Filer | Form POS EX | |
| 03/06/2026 3:36 PM | Jade Biosciences (1798749) Filer | Form POS EX | |
| 03/06/2026 3:26 PM | Jade Biosciences (1798749) Filer | Form 424B3 | |
| 03/06/2026 3:27 PM | Jade Biosciences (1798749) Filer | Form 424B3 | |
| 03/06/2026 3:15 PM | Jade Biosciences (1798749) Filer | Form 10-K Annual report pursuant to Section 13 or 15(d) | |
| 03/06/2026 6:11 AM | Jade Biosciences (1798749) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 03/05/2026 5:04 AM | Jade Biosciences (1798749) Subject Sofinnova Venture Partners X, L.P. (1680200) Filed by | Form SCHEDULE 13D/A | |
The end may be near for these iconic stocks (Ad) Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are triggering a historic wealth transfer already underway in 2026. Household names like Intuit (-57%), Boston Scientific (-49%), and Tractor Supply (-40%) are cratering, while lesser-known companies like Sandisk (+573%) and Rackspace (+444%) surge.
Chaikin has identified specific stocks he believes investors should sell before they fall further - and the names may surprise you. He's also pinpointing a company tapped as Nvidia's self-driving partner and a potential AI megadeal that could split into three high-growth stocks.
Stream his free presentation to get every buy and sell recommendation with no membership or credit card required. Watch Marc Chaikin's free presentation and get his full buy-and-sell list today |
| 02/17/2026 5:11 PM | Jade Biosciences (1798749) Subject Venrock Healthcare Capital Partners III, L.P. (1738048) Filed by | Form SCHEDULE 13G/A | |
| 02/13/2026 7:00 PM | Jade Biosciences (1798749) Issuer King Andrew James (1823187) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/13/2026 7:00 PM | Frohlich Tom (1823925) Reporting Jade Biosciences (1798749) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/13/2026 7:00 PM | Balta Elizabeth (1884087) Reporting Jade Biosciences (1798749) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/13/2026 7:00 PM | Dahms Bradford D. (1787307) Reporting Jade Biosciences (1798749) Issuer | Form 4 Statement of changes in beneficial ownership of securities | |
| 02/13/2026 7:48 AM | Deep Track Capital, LP (1856083) Filed by Jade Biosciences (1798749) Subject | Form SCHEDULE 13G/A | |
| 01/05/2026 6:17 AM | Jade Biosciences (1798749) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 12/30/2025 11:15 PM | Jade Biosciences (1798749) Filer | Form EFFECT | |
| 12/22/2025 3:38 PM | Jade Biosciences (1798749) Filer | Form S-1 Registration statement under Securities Act of 1933 | |
| 12/21/2025 11:15 PM | Jade Biosciences (1798749) Filer | Form EFFECT | |
| 12/19/2025 3:28 PM | Jade Biosciences (1798749) Filer | Form 424B3 | |
| 12/15/2025 6:11 AM | Jade Biosciences (1798749) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/14/2025 7:18 AM | Deep Track Capital, LP (1856083) Filed by Jade Biosciences (1798749) Subject | Form SCHEDULE 13G/A | |
| 11/14/2025 6:00 AM | Jade Biosciences (1798749) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |
| 11/14/2025 6:13 AM | Jade Biosciences (1798749) Filer | Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
| 10/17/2025 5:40 PM | BlackRock, Inc. (2012383) Filed by Jade Biosciences (1798749) Subject | Form SCHEDULE 13G/A | |
| 10/16/2025 6:35 PM | Jade Biosciences (1798749) Subject RA CAPITAL MANAGEMENT, L.P. (1346824) Filed by | Form SCHEDULE 13G | |
| 10/08/2025 3:15 PM | Fairmount Funds Management LLC (1802528) Reporting Fairmount Healthcare Co-Invest IV L.P. (2042283) Reporting Fairmount Healthcare Fund II L.P. (1769651) Reporting Harwin Peter Evan (1663607) Reporting Jade Biosciences (1798749) Issuer Kiselak Tomas (1830177) Reporting | Form 4 Statement of changes in beneficial ownership of securities | |
| 10/08/2025 3:15 PM | Fairmount Funds Management LLC (1802528) Filed by Jade Biosciences (1798749) Subject | Form SCHEDULE 13D/A | |
| 10/07/2025 6:13 AM | Jade Biosciences (1798749) Filer | Form 8-K Current report pursuant to Section 13 or 15(d) | |